Evidence map›Paper›PMID 33252195›Full record

ArticleEMBO reports2020

Temporal activation of LRH-1 and RAR-γ in human pluripotent stem cells induces a functional naïve-like state.

Adeleh Taei, Tahereh Kiani, Zeinab Taghizadeh, Sharif Moradi, Azam Samadian, Sepideh Mollamohammadi, Ali Sharifi-Zarchi, Stefan Guenther, Azimeh Akhlaghpour, Behrouz Asgari Abibeiglou and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in EMBO reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The Influences of RARγ on the Behavior of Normal and Cancer Stem Cells.International journal of molecular sciences · 2026
    Review
  6. Review
  7. Signaling pathway regulators in preimplantation embryos.Journal of molecular histology · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Adeleh Taei *Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Tahereh Kiani *Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Zeinab Taghizadeh *Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Sharif MoradiDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Azam SamadianDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Sepideh MollamohammadiDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Ali Sharifi-ZarchiDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Stefan GuentherDepartment of Cardiac Development and Remodeling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Azimeh AkhlaghpourDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Behrouz Asgari AbibeiglouDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Mostafa Najar-AslDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Razieh KaramzadehDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Keynoosh KhalooghiDepartment of Cardiac Development and Remodeling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Thomas BraunDepartment of Cardiac Development and Remodeling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0000-0002-6165-4804
Seyedeh-Nafiseh HassaniDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Hossein BaharvandDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.ORCID 0000-0001-6528-3687
Royan Institute · IRMax Planck Institute for Heart and Lung Research · DEUniversity of Science and Culture · IRSharif University of Technology · IR

Funding

Deutsche Forschungsgemeinschaft (DFG) B02Deutsche Forschungsgemeinschaft (DFG) SFB 1213Deutsche Forschungsgemeinschaft (DFG) SFB TRR81 TP A02Deutsche Forschungsgemeinschaft (DFG) TP A02European Research Area Network on Cardiovascular DiseasesIranian Council of Stem Cell Research and Technology (ICSCR)Iran National Science Foundation (INSF)Royan Institute
6 · The paper itself

Abstract

Naïve pluripotency can be established in human pluripotent stem cells (hPSCs) by manipulation of transcription factors, signaling pathways, or a combination thereof. However, differences exist in the molecular and functional properties of naïve hPSCs generated by different protocols, which include varying similarities with pre-implantation human embryos, differentiation potential, and maintenance of genomic integrity. We show here that short treatment with two chemical agonists (2a) of nuclear receptors, liver receptor homologue-1 (LRH-1) and retinoic acid receptor gamma (RAR-γ), along with 2i/LIF (2a2iL) induces naïve-like pluripotency in human cells during reprogramming of fibroblasts, conversion of pre-established hPSCs, and generation of new cell lines from blastocysts. 2a2iL-hPSCs match several defined criteria of naïve-like pluripotency and contribute to human-mouse interspecies chimeras. Activation of TGF-β signaling is instrumental for acquisition of naïve-like pluripotency by the 2a2iL induction procedure, and transient activation of TGF-β signaling substitutes for 2a to generate naïve-like hPSCs. We reason that 2a2iL-hPSCs are an easily attainable system to evaluate properties of naïve-like hPSCs and for various applications.

Indexed as

Pluripotent Stem CellsAnimalsBlastocystCell DifferentiationCell LineHumansMiceReceptors, Cytoplasmic and NuclearReceptors, Retinoic AcidRetinoic Acid Receptor gammaReceptors, Cytoplasmic and NuclearReceptors, Retinoic AcidRetinoic Acid Receptor gammachimera formationhuman naïve pluripotencynuclear receptorsTGF‐β signaling pathway

Identifiers

PMID33252195
PMCPMC7534641
OpenAlexW3049664936

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.